GSK plc logo
GSKGSK plc

Shares Outstanding: 2.04B

popular:market cap|pe ratio|revenue|price history|total return

The shares outstanding is 2.04B. It is above its 12-month average by 10.31% (1.85B).

Market Cap|Share Buybacks|EPS|All Metrics
Shares Outstanding

GSK Shares Outstanding

2.04B

Reported quarterly weighted average share count; no daily interpolation.

+0.89% 5Y
GSK Shares Outstanding

GSK Average Shares Outstanding Chart

GSK Shares Outstanding

GSK Current vs Average Shares Outstanding Chart

GSK Shares Outstanding Metrics

SHARES OUTSTANDING

2.04B

SHARES OUTSTANDING AVG TTM

1.85B

SHARES OUTSTANDING AVG 3Y

2.05B

SHARES OUTSTANDING AVG 5Y

2.04B

SHARES OUTSTANDING AVG 10Y

2.01B

SHARES OUTSTANDING AVG 15Y

2.00B

SHARES OUTSTANDING AVG 20Y

2.01B

CURRENT VS TTM AVG

+10.31%

CURRENT VS 3Y AVG

-0.82%

CURRENT VS 5Y AVG

-0.39%

CURRENT VS 10Y AVG

+1.14%

CURRENT VS 15Y AVG

+1.80%

CURRENT VS 20Y AVG

+1.30%

Share Structure

Shares Outstanding

1.01B

Float Shares

N/A

Stock Price

$52.50

Market Cap

$105.2B

Quarterly Shares Outstanding History

PeriodWeighted Average SharesQoQ Change
Q1 20262.04B+99.41%
Q4 20251.02B-50.20%
Q3 20252.05B-0.19%
Q2 20252.06B-0.65%
Q1 20252.07B-0.19%
Q4 20242.07B+1.59%
Q3 20242.04B-1.02%
Q2 20242.06B+0.22%
Q1 20242.06B-0.11%
Q4 20232.06B+0.14%
Q3 20232.06B+0.46%
Q2 20232.05B+0.20%
Q1 20232.04B-0.15%
Q4 20222.05B+0.07%
Q3 20222.04B+0.59%
Q2 20222.03B-0.05%
Q1 20222.03B-0.23%
Q4 20212.04B+0.52%
Q3 20212.03B+0.40%
Q2 20212.02B+0.21%
Q1 20212.01B-0.10%
Q4 20202.02B+0.04%
Q3 20202.02B+0.34%
Q2 20202.01B+0.26%
Q1 20202.00B-0.24%
Q4 20192.01B+0.30%
Q3 20192.00B+0.32%
Q2 20192.00B+0.26%
Q1 20191.99B+0.00%
Q4 20181.99B+0.12%
Q3 20181.99B+0.22%
Q2 20181.98B+0.32%
Q1 20181.98B+1.10%
Q4 20171.96B-0.89%
Q3 20171.97B+0.98%
Q2 20171.95B-0.63%
Q1 20171.97B+0.06%
Q4 20161.97B+0.27%
Q3 20161.96B+0.88%
Q2 20161.94B-0.63%
Q1 20161.96B+1.07%
Q4 20151.94B-0.80%
Q3 20151.95B+0.06%
Q2 20151.95B+0.27%
Q1 20151.94B+0.02%
Q4 20141.94B-0.10%
Q3 20141.95B-0.18%
Q2 20141.95B+0.16%
Q1 20141.95B-0.31%
Q4 20131.95B-0.85%
Q3 20131.97B+0.10%
Q2 20131.97B+1.46%
Q1 20131.94B-1.34%
Q4 20121.97B-1.19%
Q3 20121.99B-0.48%
Q2 20122.00B-0.77%
Q1 20122.01B+0.18%
Q4 20112.01B-0.65%
Q3 20112.02B-1.19%
Q2 20112.05B-0.37%
Q1 20112.06B+1.04%
Q4 20102.03B-0.78%
Q3 20102.05B+0.00%
Q2 20102.05B+0.04%
Q1 20102.05B+1.07%
Q4 20092.03B-0.74%
Q3 20092.04B+0.02%
Q2 20092.04B-0.02%
Q1 20092.04B-0.03%
Q4 20082.04B-0.71%
Q3 20082.06B-2.39%
Q2 20082.11B-2.39%
Q1 20082.16B-2.69%
Q4 20072.22B-0.84%
Q3 20072.24B-0.03%
Q2 20072.24B-1.11%
Q1 20072.26B+1.13%
Q4 20062.24B-1.01%
Q3 20062.26B-1.26%
Q2 20062.29B+0.16%
Q1 20062.29B+1.08%
Q4 20052.26B-0.39%
Q3 20052.27B-0.73%
Q2 20052.29B-0.12%
Q1 20052.29B+0.09%
Q4 20042.29B-0.17%
Q3 20042.29B-0.59%
Q2 20042.31B+0.00%
Q1 20042.31B+0.00%
Q4 20032.31B+0.00%
Q3 20032.31B-1.20%
Q2 20032.34B+0.00%
Q1 20032.34B+0.00%
Q4 20022.34B+0.00%
Q3 20022.34B-2.39%
Q2 20022.39B-

Relationship: Market Cap = Shares Outstanding × Stock Price

Key concepts:

  • Float shares: Shares available for public trading
  • Dilution: When new shares are issued, existing shareholders own less
  • Buybacks: Reduce share count, increasing EPS and ownership stake
  • Stock splits: Increase share count but don't change market cap

Shares Outstanding Formula & Definition

Shares Outstanding represents the reported weighted average share count used for per-share metrics. Changes in share count affect EPS and ownership dilution.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Shares Outstanding FAQ

What is the shares outstanding for GSK plc (GSK)?
The shares outstanding for GSK stock is 2.04B.
What is the TTM average shares outstanding for GSK plc (GSK)?
The TTM average shares outstanding for GSK stock is 1.85B.
What is the 3Y average shares outstanding for GSK plc (GSK)?
The 3Y average shares outstanding for GSK stock is 2.05B.
What is the 5Y average shares outstanding for GSK plc (GSK)?
The 5Y average shares outstanding for GSK stock is 2.04B.
What is the 10Y average shares outstanding for GSK plc (GSK)?
The 10Y average shares outstanding for GSK stock is 2.01B.
What is the 15Y average shares outstanding for GSK plc (GSK)?
The 15Y average shares outstanding for GSK stock is 2.00B.
What is the 20Y average shares outstanding for GSK plc (GSK)?
The 20Y average shares outstanding for GSK stock is 2.01B.

GSK Shares Outstanding History

DATESHARES OUTSTANDING
2026-03-312.04B
2025-12-311.02B
2025-09-302.05B
2025-06-302.06B
2025-03-312.07B
2024-12-312.07B
2024-09-302.04B
2024-06-302.06B
2024-03-312.06B
2023-12-312.06B
2023-09-302.06B
2023-06-302.05B
2023-03-312.04B
2022-12-312.05B
2022-09-302.04B
2022-06-302.03B
2022-03-312.03B
2021-12-312.04B
2021-09-302.03B
2021-06-302.02B
2021-03-312.01B
2020-12-312.02B
2020-09-302.02B
2020-06-302.01B
2020-03-312.00B
2019-12-312.01B
2019-09-302.00B
2019-06-302.00B
2019-03-311.99B
2018-12-311.99B
2018-09-301.99B
2018-06-301.98B
2018-03-311.98B
2017-12-311.96B
2017-09-301.97B
2017-06-301.95B
2017-03-311.97B
2016-12-311.97B
2016-09-301.96B
2016-06-301.94B
2016-03-311.96B
2015-12-311.94B
2015-09-301.95B
2015-06-301.95B
2015-03-311.94B
2014-12-311.94B
2014-09-301.95B
2014-06-301.95B
2014-03-311.95B
2013-12-311.95B
2013-09-301.97B
2013-06-301.97B
2013-03-311.94B
2012-12-311.97B
2012-09-301.99B
2012-06-302.00B
2012-03-312.01B
2011-12-312.01B
2011-09-302.02B
2011-06-302.05B
2011-03-312.06B
2010-12-312.03B
2010-09-302.05B
2010-06-302.05B
2010-03-312.05B
2009-12-312.03B
2009-09-302.04B
2009-06-302.04B
2009-03-312.04B
2008-12-312.04B
2008-09-302.06B
2008-06-302.11B
2008-03-312.16B
2007-12-312.22B
2007-09-302.24B
2007-06-302.24B
2007-03-312.26B
2006-12-312.24B
2006-09-302.26B
2006-06-302.29B
2006-03-312.29B
2005-12-312.26B
2005-09-302.27B
2005-06-302.29B
2005-03-312.29B
2004-12-312.29B
2004-09-302.29B
2004-06-302.31B
2004-03-312.31B
2003-12-312.31B
2003-09-302.31B
2003-06-302.34B
2003-03-312.34B
2002-12-312.34B
2002-09-302.34B
2002-06-302.39B

Related Metrics

Market CapShare BuybacksEPSAll Metrics

About GSK plc

GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.

Brentford
68,629 employees
www.gsk.com
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Luke Victor Miels
View full financials